Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial. J Infect Dis, 211, 549-557. presented at the 02/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25225676. (2015).
Safety and Immunogenicity of Ebola Virus and Marburg Virus Glycoprotein DNA Vaccines Assessed Separately and Concomitantly in Healthy Ugandan Adults: A Phase 1b, Randomised, Double-Blind, Placebo-Controlled Clinical Trial. Lancet, 385, 1545-1554. presented at the 04/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25540891. (2015).
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine, 29(2), 304-13. presented at the 2010 Dec 16. doi:10.1016/j.vaccine.2010.10.037. (2010).
A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP is Safe and Immunogenic in Healthy Adults. Vaccine, 29, 304-313. presented at the 12/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21034824. (2010).